Cardiovascular Death Essays -- Health, Treatment

IntroductionEvery year an estimated 184,000 to 400,000 Americans die from sudden cardiovascular closing due to left ventricular (LV) systolic dysfunction (Cesario & William Dec, 2006). One of the treatments of prize for the patient with a life-threating ventricular tachyarrhythmia is the automatize implantable cardioverter defibrillator (AICD). Studies cause shown that the placement of an change implantable cardioverter defibrillator (AICD) in patients with LV systolic dysfunction significantly reduces overall fatality rate rate (Cesario & William Dec, 2006 Henyan et al., 2006). Background and SignificanceOver the past 20 years the AICD adopt become more complex due to technological advances and software sophistication. Today, the recital for implantation of the AICD is rapidly expanding (Schoenfeld, 2007). The use of these cunnings in managing a diverse tribe of cardiac patients is increasing. The National ICD Registry annual report for 2008 noted that the intermedia te age of patients receiving the thingmajig was 65 years old and more than 75% of the patients have 1 or more comorbid diseases (Kaufman, R. S., Mueller, S. P., Ottenberg, L. A. & Koening. A. B., 2011 Zhan, C., Baine, B. W., Sedrakyan, A., & Steiner, C., 2007). These factors contribute to the increasing metrical composition of patients with AICD devices in the United States. In 2008, 339,076 Americans received the device, compared to 75,000 implantations in 2001 and 34,000 in 2000 (Kaufman et al., 2011). The significance for the increasing number of patients with AICDs is that anesthesia providers will be more believably to encounter this patient existence presenting for elective or emergency operative procedures. While it is the anesthesia providers duty to provide true(p)(p) and compe... ...mproved dramatically. Due to an aging universe of discourse, increasing prevalence of cardiovascular disease, and expanding distinctions for AICD therapy, the number of patients wit h AICDs presenting for functional procedure will continue to rise. Areas of concern for the anesthesia provider with this patient world include preoperative device interrogation, perioperative reprogramming, disabling of the antitachydardia function, and post operative device interrogation. While there are currently no set standards in providing anesthesia care for this patient population, the result of this evidence based go steady demonstrate that patients with AICDs presenting for cognitive operation can be safely cared for during the operative period. It is the righteousness of the anesthesia provider to be aware of the best evidence with bet to patients with AICDs in place that require anesthetic management. Cardiovascular Death Essays -- Health, preachingIntroductionEvery year an estimated 184,000 to 400,000 Americans die from sudden cardiovascular destruction due to left ventricular (LV) systolic dysfunction (Cesario & William Dec, 2006). One of t he treatments of prime(a) for the patient with a life-threating ventricular tachyarrhythmia is the automated implantable cardioverter defibrillator (AICD). Studies have shown that the placement of an automated implantable cardioverter defibrillator (AICD) in patients with LV systolic dysfunction significantly reduces overall mortality (Cesario & William Dec, 2006 Henyan et al., 2006). Background and SignificanceOver the past 20 years the AICD have become more complex due to technological advances and software sophistication. Today, the indication for implantation of the AICD is rapidly expanding (Schoenfeld, 2007). The use of these devices in managing a diverse population of cardiac patients is increasing. The National ICD Registry annual report for 2008 noted that the bonnie age of patients receiving the device was 65 years old and more than 75% of the patients have 1 or more comorbid diseases (Kaufman, R. S., Mueller, S. P., Ottenberg, L. A. & Koening. A. B., 2011 Zhan, C., B aine, B. W., Sedrakyan, A., & Steiner, C., 2007). These factors contribute to the increasing numbers pool of patients with AICD devices in the United States. In 2008, 339,076 Americans received the device, compared to 75,000 implantations in 2001 and 34,000 in 2000 (Kaufman et al., 2011). The subtraction for the increasing number of patients with AICDs is that anesthesia providers will be more probably to encounter this patient population presenting for elective or emergency surgical procedures. While it is the anesthesia providers duty to provide safe and compe... ...mproved dramatically. Due to an aging population, increasing prevalence of cardiovascular disease, and expanding indications for AICD therapy, the number of patients with AICDs presenting for surgery will continue to rise. Areas of concern for the anesthesia provider with this patient population include preoperative device interrogation, perioperative reprogramming, disabling of the antitachydardia function, and post operative device interrogation. While there are currently no set standards in providing anesthesia care for this patient population, the result of this evidence based despatch demonstrate that patients with AICDs presenting for surgery can be safely cared for during the operative period. It is the duty of the anesthesia provider to be aware of the best evidence with pick up to patients with AICDs in place that require anesthetic management.